Who
Ameet Mallik
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, ADC Therapeutics SA; Director, Atara Biotherapeutics; Chief Executive Officer, Rafael Holdings.
In numbers
- Trades disclosed
- 20
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $133K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 27 May 2021
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —675,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | —675,000 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | $3.6M900,000 at $3.99 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $412K103,231 at $3.99 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | $3.6M900,000 at $3.99 | filing |
| 13 Feb 2026filed 18 Feb 2026 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $412K103,231 at $3.99 | filing |
| 6 Dec 2025filed 9 Dec 2025 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $767K233,146 at $3.29 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —7,828 at $0.00 | filing |
| 6 May 2025filed 8 May 2025 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $35K26,758 at $1.29 | filing |
| 13 Feb 2025filed 14 Feb 2025 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code A | $1.0M650,000 at $1.61 | filing |
| 6 Dec 2024filed 9 Dec 2024 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Code F | $746K238,343 at $3.13 | filing |
| 7 May 2024filed 9 May 2024 | ADCT ADC Therapeutics SABiotechnology | SEC FORM 4 Sold | $133K29,731 at $4.48 | filing |
| 31 Mar 2024filed 2 Apr 2024 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 31 May 2023filed 2 Jun 2023 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —79,500 at $0.00 | filing |
| 31 May 2023filed 2 Jun 2023 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —57,000 at $0.00 | filing |
| 23 Jun 2022filed 27 Jun 2022 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,500 at $0.00 | filing |
| 23 Jun 2022filed 27 Jun 2022 | ATRA Atara BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —20,500 at $0.00 | filing |
| 1 Feb 2022filed 12 Apr 2022 | RFL Rafael HoldingsBiotechnology | SEC FORM 4 Code D | —908,497 at $0.00 | filing |
| 9 Aug 2021filed 10 Aug 2021 | ATRA Atara Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 27 May 2021filed 28 May 2021 | RFL Rafael HoldingsBiotechnology | SEC FORM 4 Code A | $40.6M908,497 at $44.70 | filing |
News
Head to Head Survey: Kymera Therapeutics (NASDAQ:KYMR) versus ADC Therapeutics (NYSE:ADCT)ADCT · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Ameet Mallik; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.